Detailed Mechanism Funding and Narrative

Years of mechanism: 2013 2014 2015 2016 2017

Details for Mechanism ID: 16585
Country/Region: Central America Region
Year: 2017
Main Partner: University Research Corporation, LLC
Main Partner Program: NA
Organizational Type: Private Contractor
Funding Agency: HHS/CDC
Total Funding: $1,384,988 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $340,176
Care: TB/HIV (HVTB) $1,044,812
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 3
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 5
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 6
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 5
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 8
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 19
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 17
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 4
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 13
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2018 11
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2018 24
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2018 23
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2018 4
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2018 18
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2018 11
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2018 24
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2018 23
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2018 4
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2018 18
TB_ART_den Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 3
TB_ART_den Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 5
TB_ART_den Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 6
TB_ART_den Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 5
TB_ART_den Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 8
TB_ART_den Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 19
TB_ART_den Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 17
TB_ART_den Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 4
TB_ART_den Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 13
TB_PREV By Age/Sex (Numerator): <15, Female 2018 1
TB_PREV By Age/Sex (Numerator): <15, Female 2018 4
TB_PREV By Age/Sex (Numerator): <15, Female 2018 5
TB_PREV By Age/Sex (Numerator): <15, Female 2018 1
TB_PREV By Age/Sex (Numerator): <15, Female 2018 6
TB_PREV By Age/Sex (Numerator): <15, Male 2018 2
TB_PREV By Age/Sex (Numerator): <15, Male 2018 4
TB_PREV By Age/Sex (Numerator): <15, Male 2018 9
TB_PREV By Age/Sex (Numerator): <15, Male 2018 2
TB_PREV By Age/Sex (Numerator): <15, Male 2018 7
TB_PREV By Age/Sex (Numerator): 15+, Female 2018 47
TB_PREV By Age/Sex (Numerator): 15+, Female 2018 110
TB_PREV By Age/Sex (Numerator): 15+, Female 2018 205
TB_PREV By Age/Sex (Numerator): 15+, Female 2018 45
TB_PREV By Age/Sex (Numerator): 15+, Female 2018 194
TB_PREV By Age/Sex (Numerator): 15+, Male 2018 55
TB_PREV By Age/Sex (Numerator): 15+, Male 2018 129
TB_PREV By Age/Sex (Numerator): 15+, Male 2018 241
TB_PREV By Age/Sex (Numerator): 15+, Male 2018 53
TB_PREV By Age/Sex (Numerator): 15+, Male 2018 228
TB_PREV By Therapy type (Numerator): 6-12 Month IPT 2018 105
TB_PREV By Therapy type (Numerator): 6-12 Month IPT 2018 247
TB_PREV By Therapy type (Numerator): 6-12 Month IPT 2018 460
TB_PREV By Therapy type (Numerator): 6-12 Month IPT 2018 101
TB_PREV By Therapy type (Numerator): 6-12 Month IPT 2018 435
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2018 105
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2018 247
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2018 460
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2018 101
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2018 435
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2018 121
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2018 283
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2018 529
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2018 117
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2018 501
TB_PREV_den By Age/Sex (Denominator): <15, Female 2018 2
TB_PREV_den By Age/Sex (Denominator): <15, Female 2018 4
TB_PREV_den By Age/Sex (Denominator): <15, Female 2018 7
TB_PREV_den By Age/Sex (Denominator): <15, Female 2018 2
TB_PREV_den By Age/Sex (Denominator): <15, Female 2018 6
TB_PREV_den By Age/Sex (Denominator): <15, Male 2018 2
TB_PREV_den By Age/Sex (Denominator): <15, Male 2018 5
TB_PREV_den By Age/Sex (Denominator): <15, Male 2018 8
TB_PREV_den By Age/Sex (Denominator): <15, Male 2018 2
TB_PREV_den By Age/Sex (Denominator): <15, Male 2018 8
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2018 54
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2018 126
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2018 236
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2018 52
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2018 224
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2018 63
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2018 148
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2018 278
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2018 61
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2018 263
TB_PREV_den By Therapy type (Denominator): 6-12 Month IPT 2018 121
TB_PREV_den By Therapy type (Denominator): 6-12 Month IPT 2018 283
TB_PREV_den By Therapy type (Denominator): 6-12 Month IPT 2018 529
TB_PREV_den By Therapy type (Denominator): 6-12 Month IPT 2018 117
TB_PREV_den By Therapy type (Denominator): 6-12 Month IPT 2018 501
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2018 210
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2018 492
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2018 1,534
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2018 338
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2018 1,170
TX_TB Number of ART patients who were started on TB treatment during the reporting period 2018 9
TX_TB Number of ART patients who were started on TB treatment during the reporting period 2018 47
TX_TB Number of ART patients who were started on TB treatment during the reporting period 2018 88
TX_TB Number of ART patients who were started on TB treatment during the reporting period 2018 26
TX_TB Number of ART patients who were started on TB treatment during the reporting period 2018 156
TX_TB Numerator: By Aggregated Age/Sex: <15, Female 2018 2
TX_TB Numerator: By Aggregated Age/Sex: <15, Female 2018 2
TX_TB Numerator: By Aggregated Age/Sex: <15, Male 2018 2
TX_TB Numerator: By Aggregated Age/Sex: <15, Male 2018 1
TX_TB Numerator: By Aggregated Age/Sex: <15, Male 2018 3
TX_TB Numerator: By Aggregated Age/Sex: 15+, Female 2018 4
TX_TB Numerator: By Aggregated Age/Sex: 15+, Female 2018 21
TX_TB Numerator: By Aggregated Age/Sex: 15+, Female 2018 39
TX_TB Numerator: By Aggregated Age/Sex: 15+, Female 2018 12
TX_TB Numerator: By Aggregated Age/Sex: 15+, Female 2018 70
TX_TB Numerator: By Aggregated Age/Sex: 15+, Male 2018 5
TX_TB Numerator: By Aggregated Age/Sex: 15+, Male 2018 24
TX_TB Numerator: By Aggregated Age/Sex: 15+, Male 2018 46
TX_TB Numerator: By Aggregated Age/Sex: 15+, Male 2018 14
TX_TB Numerator: By Aggregated Age/Sex: 15+, Male 2018 81
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2018 3
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2018 7
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2018 21
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2018 5
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2018 16
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2018 3
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2018 8
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2018 25
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2018 5
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2018 19
TX_TB_den Denominator: By Aggregated Age/Sex: 15+, Female 2018 94
TX_TB_den Denominator: By Aggregated Age/Sex: 15+, Female 2018 219
TX_TB_den Denominator: By Aggregated Age/Sex: 15+, Female 2018 684
TX_TB_den Denominator: By Aggregated Age/Sex: 15+, Female 2018 151
TX_TB_den Denominator: By Aggregated Age/Sex: 15+, Female 2018 522
TX_TB_den Denominator: By Aggregated Age/Sex: 15+, Male 2018 110
TX_TB_den Denominator: By Aggregated Age/Sex: 15+, Male 2018 258
TX_TB_den Denominator: By Aggregated Age/Sex: 15+, Male 2018 804
TX_TB_den Denominator: By Aggregated Age/Sex: 15+, Male 2018 177
TX_TB_den Denominator: By Aggregated Age/Sex: 15+, Male 2018 613
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay 2018 18
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay 2018 55
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay 2018 12
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay 2018 42
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay 2018 8
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert) 2018 12
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert) 2018 36
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert) 2018 8
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert) 2018 28
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert) 2018 4
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only 2018 30
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only 2018 93
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only 2018 21
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only 2018 70
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only 2018 13
TX_TB_den Denominator: By Screen Result: Negative 2018 418
TX_TB_den Denominator: By Screen Result: Negative 2018 1,304
TX_TB_den Denominator: By Screen Result: Negative 2018 287
TX_TB_den Denominator: By Screen Result: Negative 2018 995
TX_TB_den Denominator: By Screen Result: Negative 2018 179
TX_TB_den Denominator: By Screen Result: Positive 2018 74
TX_TB_den Denominator: By Screen Result: Positive 2018 230
TX_TB_den Denominator: By Screen Result: Positive 2018 51
TX_TB_den Denominator: By Screen Result: Positive 2018 175
TX_TB_den Denominator: By Screen Result: Positive 2018 31
TX_TB_den Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2018 60
TX_TB_den Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2018 184
TX_TB_den Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2018 41
TX_TB_den Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2018 140
TX_TB_den Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2018 25
Cross Cutting Budget Categories and Known Amounts Total: $19,240
Gender: Gender Based Violence (GBV) $19,240
GBV Prevention